Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: A replication study

Current Medical Research and Opinion

Volumn 27, Issue 10, 2011, Pages 1859-1867

  Gaynor, Paula J ^a   Gopal, Murali ^b   Zheng, Wei ^a   Martinez, James M ^a   Robinson, Michael J ^a   Hann, Danette ^c   Marangell, Lauren B ^a,d  

^a ELI LILLY AND COMPANY   (United States)

^b DWA Healthcare Communications Group   (United States)

^c SYNEOS HEALTH   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Duloxetine; Major depressive disorder; Pain; Randomized clinical trial

Indexed keywords

DULOXETINE; PLACEBO;

ADULT; ARTICLE; BRIEF PAIN INVENTORY; COMORBIDITY; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; EVALUATION; FATIGUE; FEMALE; HUMAN; HYPERHIDROSIS; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; NONCARDIAC CHEST PAIN; OUTCOME ASSESSMENT; OUTPATIENT; PAIN; PAIN ASSESSMENT; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; REPLICATION STUDY; SIDE EFFECT; SOMNOLENCE; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PAIN; PUERTO RICO; REMISSION INDUCTION; THIOPHENES; TIME FACTORS; UNITED STATES;

EID: 80052985439     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.609540     Document Type: Article

References (16)

1. Bair MJ, Robinson RL, Katon W, et al. Depression and pain comorbidity: a literature review. Arch Intern Med 2003;163:2433-45 (Pubitemid 37385786)
2. Bair MJ, Robinson RL, Eckert GJ, et al. Impact of pain on depression treatment response in primary care. Psychosom Med 2004;66:17-22 (Pubitemid 38146528)
3. Vaccarino AL, Sills TL, Evans KR, et al. Multiple pain complaints in patients with major depressive disorder. Psychosom Med 2009;71:159-62
4. Fava M, Mallinckrodt CH, Detke MJ, et al. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 2004;65:521-30
5. Munoz RA, McBride ME, Brnabic AJ, et al. Major depressive disorder in Latin America: the relationship between depression severity, painful somatic symptoms, and quality of life. J Affect Disord 2005;86:93-8 (Pubitemid 40487965)
6. Cymbalta prescribing information. 2011. Available at: http://www.cymbalta.com/index.jsp [Last accessed July 2011]
7. Gaynor PJ, Gopal M, Zheng W, et al. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms. Curr Med Res & Op 2011;27:1859-68
8. Brannan SK, Mallinckrodt CH, Brown EB, et al. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005;39:43-53 (Pubitemid 39422285)
9. Brecht S, Courtecuisse C, Debieuvre C, et al. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. J Clin Psychiatry 2007;68: 1707-16 (Pubitemid 350247500)
10. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-38
11. Montgomery SA,A°sberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9 (Pubitemid 9136500)
12. Dmitrienko A, Offen WW, Westfall PH. Gatekeeping strategies for clinical trials that do not require all primary effects to be significant. Stat Med 2003; 22:2387-400 (Pubitemid 36949661)
13. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11(Suppl 3):89-95 (Pubitemid 26373761)
14. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville (MD): National Institute of Mental Health, Early Clinical Drug Evaluation, Psychopharmacology Research Branch, 1976
15. Farrar JT, Young Jr JP, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58 (Pubitemid 33016608)
16. Posner K, Oquendo MA, Gould M, et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 2007; 164:1035-43 (Pubitemid 47121392)